HCPCS code J9048: Bortezomib injection, fresenius Kabi, per 0.1 mg2026 Medicare rate & RVUs in Illinois
Reports Fresenius Kabi bortezomib administered for conditions such as multiple myeloma, with each HCPCS unit representing 0.1 mg.
CMS doesn’t publish an office rate for J9048 in Illinois.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9048 covers
This HCPCS Level II code identifies injectable bortezomib supplied by Fresenius Kabi. Bortezomib is used in cancer treatment, including for multiple myeloma and mantle cell lymphoma, and is administered intravenously or subcutaneously. Oncology practices and other clinicians administering the drug report the code for the specific product furnished; it distinguishes this product from bortezomib products assigned other HCPCS codes.
CMS excludes J9048 from the physician fee schedule under status E. When Medicare covers the drug, payment is made under another method; as a Part B drug, it generally uses CMS quarterly Average Sales Price drug pricing files. Coverage is left to the Medicare contractor’s judgment. Each unit represents 0.1 mg, so 1 mg corresponds to 10 units. Report units based on the amount of this product administered.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9048 pays more and less in Illinois
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Chicago, IL | Unavailable | Unavailable |
| East St. Louis, IL | Unavailable | Unavailable |
| Rest of Illinois | Unavailable | Unavailable |
| Suburban Chicago, IL | Unavailable | Unavailable |
How the J9048 rate is calculated
Each of J9048’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9048
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9048
J9048 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9048
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9048 isn’t priced in this setting.
J9048 compared with similar codes
Compare codes · National
5 codes, side by side
How to choose
- J9041Bortezomib injectionPer 0.1 mg
- J9048 identifies Fresenius Kabi bortezomib; J9041 identifies a different product. Select the code matching the product furnished.
- J9046Bortezomib injectionDr. Reddy's, per 0.1 mg
- J9046 identifies Dr. Reddy’s bortezomib, while J9048 identifies the Fresenius Kabi product.
- J9049Bortezomib injectionHospira product, per 0.1 mg
- J9049 identifies Hospira bortezomib. Use J9048 for the Fresenius Kabi product.
- J9054Bortezomib injectionBoruzu, per 0.1 mg
- J9054 identifies Boruzu bortezomib; J9048 identifies the Fresenius Kabi product.
J9048 billing questions
When should J9048 be used instead of J9041?
Use J9048 for the Fresenius Kabi bortezomib product. J9048 is identified as not therapeutically equivalent to the product identified by J9041.
How many units represent 1 mg?
Each unit represents 0.1 mg, so 1 mg is reported as 10 units.
Which administration routes are used for bortezomib?
Bortezomib may be administered intravenously or subcutaneously. Report the amount of the Fresenius Kabi product administered.
Is J9048 paid under the physician fee schedule?
No. CMS assigns status E, excluding it from the physician fee schedule; when Medicare covers the drug, payment is under another method.
How does Medicare determine coverage for J9048?
Coverage is left to the Medicare contractor’s judgment. When covered as a Part B drug, it generally uses CMS quarterly Average Sales Price drug pricing files.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9048 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist